About this trial
Takayasu arteritis (TA) is a chronic large-vessel vasculitis that mainly affects the aorta and its major branches. The epidemiology and pathophysiology of TA is still unclear in China, although many studies have been done. Our previous study supporting by National Natural Science Foundation of China indicated the cytokines such as hs-CRP, NT-proBNP and tumor necrosis factor-alpha (TNF-α) can be used to monitor TA activity, and HLA gene alleles were associated with TA in Chinese han population. Further investigations with larger samples are needed to fully understand the a pathophysiology of TA. The purpose of this study is to build a Chinese national registry system for TA to obtain real-world information, such as current status of characteristics, diagnosis, disease activity, the severity of disease, treatment and outcomes of Chinese TA patients. To analysis and development of effective disease monitoring and treatment strategies.
Eligibility criteria
Qualifiers
Age at disease onset < 40 years. (Development of symptoms or findings related to Takayasu arteritis at age <40 years)
Claudication of extremities. (Development and worsening of fatigue and discomfort in muscles of 1 or more extremity while in use, especially the upper extremities)
Decreased brachial artery pulse. (Decreased pulsation of 1 or both brachial arteries)
BP difference >10 mm Hg. (Difference of >10 mm Hg in systolic blood pressure between arms)
Disqualifiers
Vessel lesions that could be entirely due to atherosclerosis.
Giant cell arteritis or other infectious forms of large vessel vasculitis.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
Aimin Dang
Lead sponsor
Chinese Academy of Medical Sciences, Fuwai Hospital
Sponsor institution